Silence Therapeutics reports positive Phase 2 results for divesiran

Silence Therapeutics announced that divesiran met its primary efficacy endpoint in a Phase 2 trial for polycythemia vera, with high response rates and no new safety findings. This achievement supports its potential best-in-class profile and anticipates the initiation of a Phase 3 trial later this year.